Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.70 USD
Change Today +0.01 / 0.59%
Volume 212.5K
PTIE On Other Exchanges
Symbol
Exchange
PTIE is not on other exchanges.
As of 5:20 PM 07/6/15 All times are local (Market data is delayed by at least 15 minutes).

pain therapeutics inc (PTIE) Key Developments

Pain Therapeutics Inc. Provides Update on Class Action Suit

On December 2, 2011, a securities-related purported class action was filed against Pain Therapeutics Inc. and its executive officers in the U.S. District Court for the Western District of Texas. This action, titled KB Partners I, L.P., Individually and on behalf of all others similarly situated v. Pain Therapeutics Inc., Remi Barbier, Nadav Friedmann and Peter S. Roddy, was scheduled for trial by court order dated June 23, 2015. Trial is to occur on July 7, 2015 through July 9, 2015 and continue on July 13, 2015 to July 14, 2015. In an order dated June 16, 2015, the U.S. District Court for the Western District of Texas denied a motion for summary judgment filed by Defendants concluding that there were genuine disputes of material fact for a jury to resolve in a class action alleging violations of Section 10(b), Rule 10b-5, and Section 20(a) of the Exchange Act. The company continue to believe it has substantial defenses in this matter. As with any litigation proceeding, it cannot predict with certainty the eventual outcome of this matter.

Pain Therapeutics Inc.(NasdaqGS:PTIE) dropped from Russell 2000 Index

Pain Therapeutics Inc. will be removed from Russell 2000 Index

Pain Therapeutics Inc.(NasdaqGS:PTIE) dropped from Russell 3000 Index

Pain Therapeutics Inc. will be removed from the Russell 3000 Index.

Pain Therapeutics Announces Positive Results from Drug Abuse Study

Pain Therapeutics Inc. announced positive results from an FDA Category 3 Human Abuse Potential Study with REMOXY extended-release capsules CII, which is designed to discourage certain common methods of drug tampering and misuse. This study demonstrated with statistical significance (p < 0.0001) that both intact and chewed REMOXY were less "liked" than immediate-release oxycodone on the two primary endpoints, Drug Liking and Drug High. The Abuse Potential study was conducted in non-dependent, recreational opioid users, as recommended by FDA guidelines.

Pain Therapeutics Inc. - Special Call

To discuss progress across its portfolio of drug candidates and to respond to questions

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PTIE:US $1.70 USD +0.01

PTIE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PTIE.
View Industry Companies
 

Industry Analysis

PTIE

Industry Average

Valuation PTIE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PAIN THERAPEUTICS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.